1. Study identification
EU PAS Register NumberEUPAS5160
Official titleA regional project to reduce adverse drug reactions due to medication errors in hospital
Study title acronym
Study typeObservational study
Brief description of the studyBackground: Medication errors are one of the most common types of medical error. A medication error is a failure in the treatment process that leads to, or has the potential to lead to, harm to the patient. Prescription errors account for 70% of medication errors that could potentially result in adverse drug effects.
Objectives: A study has been projected to evaluate the incidence of adverse drug reactions (ADRs) due to medication errors in hospitalized patients before and after educational audits.
Methods: All patients, aged ≥18 years, hospitalized in seven unit (three internal medicine and four geriatric) of the University Hospital of Verona during 3 months period (February- April 2013) were included in this study. The project was articled in 3 phases. In the first one, three monitors registered all ADRs occurred during hospital stay. Two panel of experts (6 physicians, 2 pharmacists and 2 pharmacologists) established, evaluating the available clinic information (e.g. clinical sheet) of all patients and according the Schumock and Thornton algorithm, if the ADRs were due to medication errors or not, in the case of error they identified the cause. At first the two panel worked separately, at a later stage a data condivision has been done to have shared data. In the second phase, educational audits directed to health care practitioners have been organized, and tools (e.g., check-list) to reduce the medication errors have been proposed. The third phase, that is similar to the first one and takes account of tools, is in progress.
Preliminary Results: Preliminary data of the first phase showed that 1474 have been enrolled in the seven units involved; the analysis has been done for 1009 patients (68%) (median age: 76 years old with DS ± 15,2; female: 51%) who gave their informed consent. Three monitors registered 180 ADRs occurred in 1009 hospitalized patients, two panel evaluated 55 ADRs (30% of 180) as avoidable. Further results will be published as available.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupPharmacology Unit - Veneto Pharmacovigilance Centre
Organisation/affiliationUniversity Hospital Verona
Details of (Primary) lead investigator
Title Professor
Last name Ugo
First name Moretti
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
Italy
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/01/201101/01/2011
Start date of data collection04/02/201304/02/2013
Start date of data analysis03/06/201303/06/2013
Date of interim report, if expected
Date of final study report30/06/201430/11/2016
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government bodyItalian Medicines Agency100
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Velo
First name Giampaolo
Address line 1Pharmacology Unit
Address line 2Policlinico GB Rossi
Address line 3P.le L.A. Scuro 10
CityVerona
Postcode37134
CountryItaly
Phone number (incl. country code)390458127450
Alternative phone number390458127451
Fax number (incl. country code)390458124876
Public Enquiries
Title Professor
Last name Velo
First name Giampaolo
Address line 1Pharmacology Unit
Address line 2Policlinico GB Rossi
Address line 3P.le L.A. Scuro 10
CityVerona
Postcode37134
CountryItaly
Phone number (incl. country code)390458027450
Alternative phone number390458127450
Fax number (incl. country code)390458124876
6. Study drug(s) information
Not applicable (disease/epidemiology study)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects3000
Additional information
All patients, aged ≥18 years, consecutively hospitalized in seven unit (three internal medicine and four geriatric) of the University Hospital of Verona during 3 months period (February- April 2013) were included in this study. The project was articled in 3 phases. For each phase we estimated to enroll about 1500 patients.
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Prospective patient-based data collection
11. Scope of the study
What is the scope of the study?
Risk assessment
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
The main objective of this study is to evaluate if educational audits organized in the second phase and directed to health care practitioners have reduced the medication errors due to adverse drug reaction in the third phase.
Are there primary outcomes?Yes
All adverse drug reactions registered in all hospitalized patients during the study period and in the involved units
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Not applicable/no follow-up
15. Data analysis plan
Please provide a brief summary of the analysis method
A descriptive analysis will be conducted for all variables. The risk factors for ADRs and medication errors will be identified by studying the effects of age, the sex, the duration of stay in the department and the severity of ADRs. The results will be expressed in terms of Odds Ratio (OR) with their 95% confidence intervals (95% CI). The level of significance will be estimated at 5%.